This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
23 May 2011

BioAegis Signs Agreement for Human Protein in Clinical Development

BioAegis Therapeutics have entered into an exclusive option agreement with Brigham and Women's Hospital for therapeutic and diagnostic technology for human and animal applications.

Privately held BioAegis Therapeutics has signed an exclusive option agreement with Brigham and Women’s Hospital granting BioAegis a worldwide license for therapeutic and diagnostic use of Brigham’s technology for human and animal applications.

 

The technology is based on the research of founding scientist Dr. Thomas Stossel, director, Translational Medicine at Brigham and Women’s Hospital, and collaborators at Massachusetts General Hospital, University of Pennsylvania, Beth Israel Deaconess Medical Center and BloodCenter of Wisconsin.

 

Dr. Stossel said, “Plasma gelsolin is just beginning to reveal its fundamental role in immune function and inflammation. BioAegis is committed to a broad set of translational objectives which promise to deli

Related News